Peptide Cycling for Long-Term Bodybuilding Use

Why lifters cycle peptides

Most lifters who use growth hormone peptides for years don't run them nonstop. They use them in blocks, often 8-16 weeks long, then stop or switch compounds. Forum guides usually give tolerance as the reason: users describe the first weeks as noticeably different, and by the third month many say the effect has faded.

The usual explanation is receptor desensitization. When a receptor is stimulated constantly, cells can pull it off their surface or uncouple it from its signaling machinery, so the same dose produces a smaller response. That's well-described biology for many hormone receptors. What's less clear is how much of it happens with the peptides lifters use, at the doses they use, over months. The human evidence is thin, and some of it points the other way.

This page covers what the few multi-week and multi-year human studies found and which on/off schedules users describe. For long-term risks and benefits more broadly, see our overview of long-term peptide effects in bodybuilding.

How desensitization could apply to GH peptides

The peptides lifters cycle most fall into two groups. GHRH analogues such as CJC-1295 and sermorelin act on the pituitary's GHRH receptor. GHRPs and other ghrelin mimetics, such as ipamorelin, hexarelin and the oral compound MK-677 (ibutamoren), act on the ghrelin receptor (GHSR-1a). Both groups raise growth hormone (GH), and repeated dosing raises IGF-1, which carries much of GH's effect on muscle and other tissue.

Constant stimulation at either receptor could, in theory, blunt the pituitary's response. There's a second brake as well: rising GH and IGF-1 feed back on the hypothalamus and pituitary, increasing somatostatin and damping further GH release.

A fading effect may also have nothing to do with receptors. Expectation effects wear off, and a gray-market vial may hold less peptide than its label says. Since several explanations fit the same experience, direct measurements matter more than theory. Only a handful of human studies have dosed these compounds for weeks or longer and checked whether the response held.

What the longer human studies found

Hexarelin: a partial loss that reversed

The clearest human test is a small 1998 study by Rahim and Shalet. Twelve healthy older adults received subcutaneous hexarelin twice a day for 16 weeks. Their GH response, measured as area under the curve, fell from 19.1 µg/L per hour at baseline to 10.5 at week 16, a drop of roughly 45%. Most of the decline had already appeared by week 1. Four weeks after the course ended, a fresh dose produced a response of 19.4, no different from baseline.

That's the best support in the literature for the idea that a break restores the response. The loss was partial, though, and the participants were older adults rather than young lifters. Forum users often say hexarelin tolerance sets in around 4 weeks, which roughly fits. The authors describe hexarelin as causing profound GH release, so its pattern may not carry over to milder compounds such as ipamorelin.

MK-677: two years with GH and IGF-1 still raised

The longest controlled trial in this class found no loss of effect. In a 2-year randomized, placebo-controlled trial (Nass and colleagues, Annals of Internal Medicine, 2008), 65 healthy adults aged 60-81 took 25 mg of oral MK-677 or placebo once daily. At 12 months, MK-677 had raised GH and IGF-1 into the range seen in young adults. In an exploratory 24-month analysis of 53 participants, those increases were still there.

A lasting hormone rise isn't the same as a useful one, and the trial shows the gap. Fat-free mass rose about 1.1 kg, compared with a small loss on placebo, but strength and function didn't change. Fasting glucose rose by about 5 mg/dL and insulin sensitivity fell. For someone planning years of use, that glucose finding is probably more relevant than tolerance.

CJC-1295 with DAC and the "GH bleed" claim

Community guides, including an earlier version of this page, say the DAC form of CJC-1295 causes a constant "bleed" of GH that wipes out natural pulses and speeds up desensitization. The human data don't support that.

The DAC form binds to albumin in the blood. In a 2006 study in healthy adults aged 21-61 (Teichman and colleagues), its half-life was 5.8-8.1 days. Single subcutaneous doses raised mean GH 2- to 10-fold for 6 days or more and IGF-1 1.5- to 3-fold for 9-11 days.

A companion study that year (Ionescu and Frohman) sampled GH every 20 minutes overnight in healthy men aged 20-40, before and 1 week after a single 60 or 90 µg/kg dose. The frequency and size of GH pulses didn't change. What rose was the trough, the GH level between pulses, which went up about 7.5-fold and lifted mean GH by 46%. Pulses were preserved; they sat on a higher floor.

Whether that higher floor matters over months is still unanswered, because no human study has given CJC-1295 with DAC long enough to measure desensitization. Most users actually run the short-acting form without DAC (Mod GRF 1-29), and our CJC-1295 profile explains how the two differ.

On/off schedules users report

As of October 2026, no controlled study has compared any common on/off cycle with continuous dosing. The schedules below come from forum posts and vendor guides. They describe community practice, not tested or required protocols.

The stack users mention most is Mod GRF 1-29 with ipamorelin, commonly reported at 100-300 mcg of each by subcutaneous injection near bedtime. Some describe two or three doses a day instead. We found no controlled human trial of this combination, and the bedtime timing (meant to match the natural overnight GH pulse) hasn't been tested for these peptides. Ipamorelin's own human data come from IV studies, including a Phase 2 trial after abdominal surgery that missed its primary endpoint.

Rotating compounds across a training year

Many lifters match peptide use to training phases, with GH peptides while bulking and a fat-loss peptide while cutting. The structure borrows from training periodization, but nobody has tested it as a peptide strategy.

AOD-9604 is the peptide most often slotted into a cut. Forum users most often describe 300 mcg by subcutaneous injection once daily for about 12 weeks. Its sponsor's human trials used only oral or IV dosing, and the largest (OPTIONS, oral 0.25-1 mg daily in adults with obesity) missed its 12-week weight-loss endpoint. As of October 2026 there are no human data on injected AOD-9604.

BPC-157 and TB-500 often fill the off block, on the reasoning that they don't work through the GH axis. Users commonly report 250-500 mcg a day of BPC-157 by subcutaneous injection. The evidence for both is mostly animal data: BPC-157 has three small uncontrolled human pilots, and FDA says it has found no human exposure data for the TB-500 fragment. Whether either affects GH recovery during a break has never been measured. Diet changes across these phases too, which our nutrition guide for peptide users covers.

Tracking the response over years

With so little long-term data, many experienced users treat their own bloodwork as the evidence. The markers they track most follow from the trials above:

• IGF-1, as a rough check that a GH peptide is doing anything. A flat IGF-1 after several weeks could point to a mislabeled product as easily as to desensitization.
• Fasting glucose and HbA1c, because MK-677 raised fasting glucose and lowered insulin sensitivity over 2 years.
• Metabolic and lipid panels, as general health markers.

Users most often describe testing before a block and again several weeks after stopping. Repeated over years, those results say more about one person's response than any forum schedule. A clinician can help read them, especially a glucose or HbA1c trend that keeps rising.

Sport and legal status

As of October 2026, WADA's 2026 Prohibited List bans CJC-1295, sermorelin, ipamorelin, hexarelin and ibutamoren (MK-677) at all times under S2.2.4, and names BPC-157 under S0. An off block doesn't change that for tested athletes.

In the US, FDA's list of compounding substances that may present significant safety risks includes ibutamoren, citing a congestive heart failure signal in a hip-fracture trial and higher blood glucose. Ipamorelin is on the same page for outsourcing facilities. CJC-1295 sits in its "nominated but withdrawn" table, with FDA noting raised heart rate and a vasodilatory reaction. None of these is an approved drug. Our guide to the legal side of research-use peptides covers what that means for buyers.

What we still don't know

• Whether any on/off schedule keeps the GH or IGF-1 response higher than continuous use.
• How young, trained lifters respond compared with the older adults in the hexarelin and MK-677 studies.
• What happens to the response with Mod GRF 1-29 or ipamorelin beyond a few weeks; no human study has looked.
• How much of the fading effect users notice comes from receptors and how much from expectation or product quality.